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Case Report
Severe Axillary Lymphadenitis After BCG Vaccination: 
Alert for Primary Immunodeficiencies
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aMedical Inpatient Department, Coimbra Pediatric Hospital, Coimbra, Portugal.
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The bacilli Calmette-Guérin (BCG) vaccine is administered to all newborns in countries where tuberculosis 
is endemic. Immunocompromised hosts, namely patients with human immunodeficiency virus infection 
or primary immunodeficiencies, are especially prone to serious complications from this vaccine. We 
report three cases of BCG disease in children with primary immunodeficiencies: one with a partial reces-
sive interferon-γ receptor 1 deficiency, who developed BCG dissemination; and two relatives with ZAP70 
deficiency, a severe combined immunodeficiency, both of whom presented with regional and distant BCG 
disease. All had severe axillary lymphadenitis. These clinical cases underline the importance of considering 
the diagnosis of immunodeficiency in a child with severe axillary lymphadenitis after BCG vaccination and 
of disseminated BCG disease in an immunodeficient child in the appropriate clinical setting. Moreover, 
BCG vaccination should be delayed in every newborn with a family history of primary immunodeficiency 
until the condition has been ruled out.
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Introduction
Tuberculosis incidence and mortality are increasing world-
wide, particularly in developing countries,1 where infection 
is often acquired in childhood. The human immuno-
deficiency virus (HIV) pandemic, emerging mycobacterial 
drug resistance and limitations of the bacilli Calmette-
Guérin (BCG) vaccination are contributing factors to this 
increased incidence and mortality.
The World Health Organization recommends adminis-
tering BCG vaccine to all infants as soon as possible after 
birth, in countries with a high incidence of tuberculosis.2 
Countries with a different epidemiological situation may 
choose to limit BCG vaccination to defined high-risk groups 
for the disease and to skin-test negative older children, be-
sides intensifying case detection, supervised early treatment, 
preventive treatment and infection control measures. In 
Portugal and other countries where tuberculosis is endemic, 
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the BCG vaccine is included in the national childhood im-
munization program and administered within the first 
days of life.
Severe adverse effects of BCG vaccination are ex-
tremely rare in immunocompetent children.3 In contrast, 
immunocompromised hosts such as HIV-infected indi-
viduals or those suffering a primary immunodeficiency 
(PID),4 are especially prone to complications from this 
vaccine and tend to be unresponsive to treatment. There-
fore, the World Health Organization recommendations 
have recently been reviewed concerning infants at risk for 
HIV infection.5 Commonly, PID remains undiagnosed 
at the time of BCG vaccination and has been associated 
with severe complications from this vaccine.6–8 We report 
three cases of BCG disease after vaccination in children 
with PID.
Case Reports
Case 1
A healthy girl, the first child of first cousin parents, was 
born at full term. She had two healthy maternal half-
brothers, aged 11- and 3-years-old. She was given the rou-
tine vaccinations in Portugal, including the BCG vaccine, 
in the first days of life. At the age of 3.5 months, she pre-
sented with hypovolemic shock, severe anemia, consump-
tion coagulopathy, hepatosplenomegaly and ulcerated 
left axillary lymphadenitis. Thoraco-abdominal ultrasound 
and computed tomography scans revealed heterogeneous 
splenomegaly. The transfontanelar ultrasound results and 
bone marrow cellular evaluation were normal. Serological 
studies for toxoplasma, rubella virus, herpes virus, adeno-
virus, parvovirus, cytomegalovirus, HIV and Treponema 
pallidum were negative.
She was initially prescribed ceftriaxone (100 mg/kg/day), 
which was later substituted with teicoplanin (10 mg/kg/day) 
and fluconazole (12 mg/kg/day). She was also given red 
blood cells, platelets and plasma transfusions. The possi-
bility of a giant splenic hemangioma (Kasabach-Merrit 
Syndrome) was put forward, supported by eco-Doppler 
results. Despite treatment with interferon-α and pred-
nisolone (2 mg/kg/day), splenomegaly persisted and in-
termittent high temperatures (38–39ºC) developed. A few 
weeks later, she was admitted to the intensive care unit with 
right pneumothorax, pneumonia with pneumatoceles, 
sepsis, heart failure, worsened hepatosplenomegaly, portal 
hypertension and elevated liver function tests.
During diagnostic investigations, Mycobacterium bovis 
was cultured from the drainage of the left axillary lymphad-
enitis, bone marrow, liver (Figure 1) and skin. Despite oral 
treatment with rifampicin (10 mg/kg/day), isoniazid (10 mg/
kg/day), pyrazinamide (30 mg/kg/day) and clarithromy-
cin (15 mg/kg/day) at age 5.5 months, she developed gen-
eralized BCG cutaneous lesions at the age of 14 months, 
which were confirmed by biopsy and culture. However, 
clinical improvement and reduction of the lymphadenitis 
were observed with anti-bacillar treatment.
Initial immunological assessments encompassing serum 
immunoglobulins, complement, T cell and monocyte cy-
tokine production profiles and lymphocyte subsets and 
proliferation tests were normal. Interleukin (IL)-12 receptor 
expression in CD4+ and CD8+ T cells was normal. The ex-
pression of interferon-γ receptor 1 (IFN-γR1) was decreased 
in both CD4+ and CD8+ T cells (Figure 2). A homozygous 
I87T mutation in the IFN-γR1 gene was identified, clini-
cally presenting as a partial recessive IFN-γR1 deficiency, 
as previously described.19 The child received subcutane-
ous IFN-γ (50 μg/m2 of body area) three times a week for 
10 months from the age of 8 months.
Case 2
A girl with adequate somatometry for her gestational age 
was born at full term. Her parents were first cousins, as well 
as her father’s parents (Figure 3). This girl was given BCG 
and anti-hepatitis B virus (HBV) vaccines at birth and 
anti-diphteria, tetanus, pertussis, poliomyelitis and 
Figure 1. Liver biopsy showing hepatic granuloma (hematoxylin 
and eosin, original magnification, 150×).
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Haemophylus influenza b vaccines along with a second 
dose of anti-HBV vaccine 2 months later.
At the age of 5 months, she was referred to our depart-
ment with generalized, cutaneous erythematous papules, 
which had appeared 3 months before. She also had recur-
rent wheezing and failure to thrive since the age of 3.5 
months. Upon physical examination, she had small left 
axillary lymphadenopathies.
The histopathology of the biopsied skin lesions showed 
tuberculoid granuloma (Figure 4). She further developed 
Pneumocystis jiroveci pneumonia and other less severe 
bacterial and viral recurrent infections, mainly localized 
to the respiratory tract. She was subjected to intravenous 
immunoglobulin therapy (500 mg/kg every 3 weeks) 
and prophylaxis with trimethoprim/sulphamethoxazole 
(450 mg/m2 for 3 days per week), pending bone marrow 
transplant, which the parents refused.
Serum immunoglobulins and complement test results 
were normal. Decreased numbers of CD8+ T cells (2%, 42/μL) 
and CD4+:CD8+ cell ratios (0.028) were detected. T cell 
cytokine production (IL-2 and tumor necrosis factor-α) 
after stimulation with phytohemagglutinin was absent. 
The lymphocyte transformation test was decreased for 
different mitogens. The expression of ZAP70 was normal 
in B, NK and T cells. The ZAP70 and Syk (spleen tyrosine 
kinase) western blot analysis carried out to evaluate the 
presence and phosphorylation of these two proteins re-
vealed an increase in Syk and an absence of phosphory-
lation of ZAP70. Molecular analysis showed a R170C 
mutation in the ZAP70 gene corresponding to an arginine at 
position 170, which is important in the interaction with the 
phosphorylated tyrosine in the ITAM (Immunoreceptor 
tyrosine-based activation motif) motifs of the CD3 complex 
(Taylor et al, unpublished data).
Case 3
A boy, the second son of a non-consanguineous young 
couple, was born at full term, with adequate somatometry 
for the gestational age. When he was 6 months old, he 
Figure 3. Family trees for cases 2 and 3.
Case 3
Case  2
Figure 2. Decreased expression of the IFN-γ receptor on CD4+ and CD8+ T cells analyzed by flow cytometry and compared with an 
age-matched healthy control.
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presented with acute nasopharyngitis for 5 days, and 
1 week later he presented with irritability, respiratory dis-
tress syndrome, skin pallor, peripheral and central cyano-
sis and dry cough without fever or anorexia. He had 
received only the BCG and HBV vaccinations at the ma-
ternity hospital. A large left axillary lymphadenitis was 
evident (Figure 5). He started failing to thrive at the age of 
2 months. He had a cousin with a suspected immunodefi-
ciency later diagnosed as a ZAP70 deficiency (case 2) and 
followed up in our PID clinic.
At the time of admission, the leukocyte count was 
13,620/μL (60% lymphocytes), the platelet count was 
554,000/μL, hemoglobin was at 11.2 g/dL and the C-reactive 
protein level was 0.2 mg/dL. Urine and blood cultures 
were negative. The chest radiography showed a bilateral 
interstitial pneumonia (Figure 6). He was hospitalized and 
initially treated with intravenous amoxicillin (90 mg/kg/
day) and clavulanic acid, as well as oxigenotherapy. 
Pneumocystis jiroveci was detected in the nasopharynx 
aspirate by indirect immunofluorescence. Consequently, 
he was put on ceftriaxone (100 mg/kg/day) and trimetho-
prim/sulphametoxazole (120 mg/kg/day) and an immun-
odeficiency was suspected.
Figure 4. Cutaneous tuberculoma (hematoxylin and eosin, original magnification, 25× and 100×).
25x 100x
Figure 5. Left axillary lymphadenitis in case 3.
Day 1 Day 12 Day 45
Figure 6. Bilateral pneumonia (Pneumocystis jiroveci).
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The immunological evaluation revealed increased levels 
of serum IgA (2.55 g/L) and IgM (1.77 g/L), and a decreased 
number of CD56+ (138/μL, 3%) and CD8+ (46/μL, 1%) cells. 
Serological evaluation for HIV-1 and HIV-2 was negative. 
The expression, genetic analysis and functional assessment 
of ZAP70 were similar to his cousin in case 2 (Taylor et al, 
unpublished data).
Mycobacterium bovis was isolated in the lymphadenitis 
exudate and nasopharynx aspirate. Besides anti-bacillar 
treatment with isoniazid, rifampin and etambutol, he was 
submitted to intravenous immunoglobulin therapy and 
antimicrobial prophylaxis with trimethoprim/sulphame-
toxazole. Since bone marrow transplantation was performed 
at the age of 14 months, he has thrived and developed well, 
despite minor infections.
Discussion
We report three cases of BCG disease after vaccination in 
children with PID: one with a partial recessive IFN-γR1 
deficiency, who developed BCG dissemination, and two 
with ZAP70 deficiency, a severe combined immunodefi-
ciency, who presented with regional and distant BCG dis-
ease. All had severe axillary lymphadenitis, which should 
be a sign for PID in BCG-vaccinated children.
The etiologies of infections developing in the immun-
odeficient child are an important clue to the diagnosis of 
underlying immune defects in patients with PID.9,10 Few 
PIDs confer susceptibility to mycobacteria.10 PIDs with 
high susceptibility to mycobacterial infections include 
IL-12/IFN-γ axis defects, chronic granulomatous disease, 
severe combined immunodeficiencies (SCID), idiopathic 
CD4 lymphopenia and defects of nuclear factor-kB essen-
tial modulator (NEMO)-dependent NF-kB activation. The 
latter two show increased susceptibility to tuberculosis 
and non-tuberculosis mycobacteria but not to BCG. The 
particular immune defects explain the susceptibility to 
mycobacterial infections and complications of BCG vacci-
nation, however one has to bear in mind that both tuber-
culosis and BCG disease may occur.4,11
The first reported case was an infant with a defect 
in the IL-12/IFN-γ axis, an IFN-γR1 deficiency.12,13 
The IFN-γ-IL-12/23 circuit is crucial in the immune re-
sponse to intracellular microorganisms such as Salmonella, 
Listeria, mycobacteria14 and certain viruses. Specific genetic 
mutations resulting in the impairment of this functional 
axis have been identified and include deficiency of IFN-γR1, 
the receptor which binds onto macrophages; deficiency in 
the signaling chain of the IFN-γ R2; deficiency of the 
IL-12 R subunit β1, which is expressed in T and NK cells; a 
deficiency in the p40 subunit of IL-12; and, finally, 
STAT-1 deficiency, a critical molecule in the transduction 
of signals from the IFN-γ and IFN-α/β receptors.
A correlation between the IFN-γR1 genotype, cellular 
response to IFN-γ and the clinical phenotype has been 
established.15 The autosomal dominant form is the most 
common and the least serious. Among the autosomal 
recessive forms, a complete loss of the protein expression 
or a partial defect can occur. These rare patients tend to 
develop severe mycobacterial diseases during infancy or 
childhood, as they fail to form well-circumscribed tuber-
culoid granuloma. When BCG vaccine is administered, 
disseminated infection typically develops.16 In complete 
defects, fatal infection from BCG vaccination has been 
reported.17,18
The major difficulty in these cases is that the routine 
immunological test results are normal and specific inves-
tigation of IL-12/IFN-γ axis is needed. In the reported 
case, that fact may have delayed the diagnosis. In the end, 
a homozygous I87T mutation in the IFN-γR1 gene was 
detected, which has already been described in non-related 
Portuguese children.19
The second and third patients are cases of ZAP70 defi-
ciency, a rare autosomal recessive SCID.20 ZAP70 is an in-
tracellular tyrosine kinase recruited to the CD3/T cell 
receptor and required for T cell activation following T cell 
receptor engagement. Mutations in the gene on chromo-
some 2q12 result in defective expression and/or function of 
ZAP70 and consequently, a decreased number of CD8+ cells, 
a normal number of CD4+ cells and inability of peripheral 
lymphocytes to respond to activation signals. Circulating 
B cells are normal, serum immunoglobulins may be nor-
mal or decreased and specific antibody responses are varia-
ble. Both our patients exhibited no ZAP70 phosphorylation, 
which means that despite the presence of ZAP70 protein 
in the immune cells it was not activated after encounter-
ing an antigen. Patients with ZAP70 deficiency usually 
present early in life with typical clinical features of SCID: 
severe respiratory infections, including those from op-
portunistic pathogens, chronic diarrhea, failure to thrive, 
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Table. Guidelines for classification, diagnosis and management of BCG disease in immunocompromised children4
C
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Local BCG disease
● Abscess on the BCG injection site with diameter greater or equal to 10 mm, and/or 
● Severe BCG scar ulceration
Regional BCG disease
● Involvement of vaccination site, and
●  Enlargement, suppuration and/or fistula on any regional lymph nodes (e.g. ipsilateral axillary, supraclavicular, cervical 
and upper arm glands) or other regional lesions
Distant BCG disease
●  BCG confirmed from one site beyond a local or regional ipsilateral process [e.g. pulmonary secretions (gastric or 
tracheal aspirate), cerebrospinal fluid, urine, osteitis, distant skin lesions]
Disseminated BCG disease
● BCG confirmed from more than 1 distant site and/or from at least 1 blood or bone marrow culture
D
ia
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f B
C
G
 d
is
ea
se
All children
● Detailed clinical history including documentation of local and regional BCG lesions
● Fine needle aspirate for mycobacterial culture
● HIV testing
Immunocompromised children
● Chest radiography (antero-posterior and lateral)
● Gastric washings for mycobacterial culture (minimum of 2)
● Mycobacterial blood culture (if febrile)
● CD4+ T lymphocyte count and viral load (if HIV+ and not performed in previous 2 months)
● Full blood and differential count
● Baseline liver function tests (for monitoring of toxicity)
Additional tests for immunocompromised children with suspected distant or disseminated BCG disease
● bone marrow aspirate/biopsy for mycobacterial culture
● mycobacterial blood culture (even if afebrile)
● abdominal ultrasound (for intra-abdominal lymphadenopathy)
● radiography (if osteitis is suspected)
● other systemic investigations as clinically indicated
M
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Local or regional BCG disease
● Medical treatment:
 – isoniazid 15–20 mg/kg/day
 – rifampicin 20 mg/kg/day
 – pyrazinamide 20–25 mg/kg/day (2 months until tuberculosis is excluded)
 – ethambutol 20–25 mg/kg/day
 – ofloxacin 15 mg/kg/day or ciprofloxacin 30 mg/kg/day
● Therapeutic aspiration if node fluctuant
● Excision biopsy if no improvement or deterioration of adenitis after 6 weeks of antituberculosis therapy
● If HIVC+ on HAART, ensure that HAART is antituberculosis-drug compatible
● Monitor for drug toxicity
● Report as vaccine-related adverse event to Expanded Programme on Immunization
Distant or disseminated BCG disease
● Medical treatment as above
● Consider expedited initiation of HAART
● Monitor for drug toxicity
● Report as vaccine-related adverse event to Expanded Programme on Immunization
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persistent candidiasis and oral ulcers. Unlike patients with 
other forms of SCID, these patients tend to have palpable 
lymph nodes and a normal thymic shadow.
Severe BCG disease has previously been described in 
SCID infants,8,21 including cases of cutaneous BCG dis-
semination,22 but not in children with ZAP70 deficiency. 
These cases illustrate the importance of taking a detailed 
clinical history before routine vaccination, as it would 
have been important avoid BCG vaccination in this child 
with a family history of PID, before appropriate immuno-
logical evaluation had been performed.
After Talbot et al designed a BCG disease classification 
system,6 Hesseling et al revised this system regarding the 
pediatric age group in order to more accurately reflect all 
relevant disease categories in HIV-infected and uninfected 
children.4 More recently, Bernatowska et al also proposed 
some diagnostic criteria for disseminated BCG infection in 
PID patients.7 Guidelines for the diagnosis and treatment 
of BCG disease in immunocompromised patients as rec-
ommended by Hesseling et al4 and summarized in the 
Table are be helpful for early recognition.
The practice of compulsory administration of the 
BCG vaccine early in life, as performed in many countries 
where tuberculosis is endemic, puts immunodeficient 
children at high risk of developing BCG disease, as common 
PIDs have not been diagnosed at the time of vaccination. 
BCG vaccination for all neonates should be reconsidered 
in some countries23 due to the changing epidemiology of 
tuberculosis and the poor protection that BCG vaccine 
confers. In any country, BCG vaccination should be delayed 
when a PID is suspected and/or a newborn has a family his-
tory of PID, until the same condition has been ruled out.
In summary, BCG dissemination in an immunodefi-
cient child may be the presenting clinical picture of a PID, 
and may not be associated with a local or regional disease. 
Severe axillary lymphadenitis (or any other form of BCG 
disease) after BCG vaccination should alert physicians for 
an immunodeficiency, including PID. The diagnosis of 
disseminated BCG disease should be considered in a child 
with a known PID in the appropriate clinical setting. An 
accurate diagnosis of BCG dissemination demands a 
search for specific immune defects to allow for an early 
life-saving treatment. Moreover, every adverse reaction to 
the BCG vaccine should be reported in the medical litera-
ture and to the relevant authorities. A new tuberculosis 
vaccine, more immunogenic, effective and safer than the 
old BCG vaccine, is urgently needed.24
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